

P20825.A06

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant : Yoko AIDA et al.

Group Art Unit: 1646

Serial No : 09/787,437
(National Stage of PCT/JP99/00388)

Examiner: Unknown

Filed : March 27, 2001
(International Filing Date January 29, 1999)

For : APOPTOSIS INDUCING AGENT

**RESPONSE TO PAPER DATED MARCH 27, 2002
AND
STATEMENT THAT THE CONTENT OF THE PAPER AND
COMPUTER READABLE COPIES ARE THE SAME**

Assistant Commissioner of Patents
Washington, D.C. 20231

Sir:

In response to the Notification of Defective Response dated March 27, 2002, (copy submitted herewith) which states that the "Sequence Listing" does not comply with the requirements of disclosure, reconsideration and withdrawal of the objection to the sequence listing are requested for the reasons discussed below. Inasmuch as the one-month shortened statutory period set in the Office Action is set to expire on April 29, 2002 (April 27 being a Saturday), Applicants assert this response is being timely filed. The Commissioner is hereby authorized to charge any necessary fees, such as any necessary extension of time fees, to Deposit Account No. 19-0089.

Applicant notes that paper and computer readable forms of nucleotide sequence listings are being filed herewith. In accordance with 37 C.F.R. 1.821(f), the undersigned hereby states that the information recorded in the computer readable form is identical to the written sequence listing. Applicant hereby states that the submission, filed in accordance with 37 C.F.R. 1.821(h), herein does not include new matter.


P20825.A06

In view of the above, Applicants respectfully submit that the objection to the sequence listing should be withdrawn.

If there are any comments or questions, the undersigned may be contacted at the below-listed telephone number.

April 4, 2002
GREENBLUM & BERNSTEIN, P.L.C.
1941 Roland Clarke Place
Reston, VA 20191
(703) 716-1191

Respectfully submitted,
Y. AIDA et al.



Bruce M. Bernstein
Reg. No. 29,027

Reg No 45905



UNITED STATES PATENT AND TRADEMARK OFFICE

Commissioner for Patents, Box PCT
 United States Patent and Trademark Office
 Washington, D.C. 20231
 www.uspto.gov

U.S. APPLICATION NUMBER NO.	FIRST NAMED APPLICANT	ATTY. DOCKET NO.
09/787,437	Yoko Aida	P20825

INTERNATIONAL APPLICATION NO.	
PCT/JP99/00388	
I.A. FILING DATE	PRIORITY DATE
01/29/1999	09/30/1998

7055
 GREENBLUM & BERNSTEIN, P.L.C.
 1941 ROLAND CLARKE PLACE
 RESTON, VA 20191

CONFIRMATION NO. 3769

371 FORMALITIES LETTER



OC000000007702389

Date Mailed: 03/27/2002

NOTIFICATION OF DEFECTIVE RESPONSE

The following items have been submitted by the applicant or the IB to the United States Patent and Trademark Office as an Elected Office (37 CFR 1.495):

- U.S. Basic National Fee
- Priority Document
- Assignee Statement
- Biochemical Sequence Diskette
- Biochemical Sequence Listing
- Copy of IPE Report
- Copy of references cited in ISR
- Copy of the International Application
- Copy of the International Search Report
- Information Disclosure Statements
- Oath or Declaration
- Preliminary Amendments
- Request for Immediate Examination

RECEIVED

APR 6 2002

CHINA/JP/US/UK/FR/DE

The following items **MUST** be furnished within the period set forth below in order to complete the requirements for acceptance under 35 U.S.C. 371:

Applicant is required to complete the response within a time limit of ONE MONTH from the date of this Notification or within the time remaining in the response set forth in the Notification of Missing Requirements, whichever is the longer. No extension of this time limit may be granted under 37 CFR 1.136, but the period for response set in the Notification of Missing Requirements may be extended under 37 CFR 1.136(a).

The following items **MUST** be furnished within the period set forth below:

- The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 CFR 1.821-1.825 for the following reason(s):

- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."
 - See attached Raw Sequence Listing Error Report
 - APPLICANT MUST PROVIDE:
 - An initial or substitute paper copy or compact disc of the "Sequence Listing," as well as an amendment directing its entry into the specification.
 - A statement that the contents of the paper or compact disc and the computer readable form are the same and, where applicable, include no new matter, as required by 37 CFR 1.821(e), 1.821(f), 1.821(g), 1.825(b) or 1.825(d).
- For questions regarding compliance to 37 CFR 1.821-1.825 requirements, please contact:
- For Rules Interpretation, call (703) 308-4216
 - To Purchase PatentIn Software, call (703) 306-2600
 - For PatentIn Software Program Help, call (703) 306-4119 or e-mail at patin21help@uspto.gov or patin3help@uspto.gov
- A copy of the "Sequence Listing" in computer readable form has been submitted. The content of the computer readable form, however, does not comply with the requirements of 37 CFR 1.822 and/or 1.832, as indicated on the attached marked-up copy of the "Raw Sequence Listing."

Applicant is reminded that any communications to the United States Patent and Trademark Office must be mailed to the address given in the heading and include the U.S. application no. shown above (37 CFR 1.5)

*A copy of this notice **MUST** be returned with the response.*

BARBARA A CAMPBELL

Telephone: (703) 305-3631

PART 1 - ATTORNEY/APPLICANT COPY

U.S. APPLICATION NUMBER NO.	INTERNATIONAL APPLICATION NO.	ATTY. DOCKET NO.
09/787,437	PCT/JP99/00388	P20825